A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Wiek 18 lat lub więcej
  • Zaawansowany rak pęcherza, płuc, głowy i szyi, przełyku lub trzustki
  • Możliwość zmierzenia zmian nowotworowych
  • Ogólny stan zdrowia odpowiedni do udziału (ECOG 0-1)
  • Rak powrócił lub zmienił się po wcześniejszych leczeniach
  • Ustąpienie objawów ubocznych z poprzedniego leczenia
  • Zgoda na dostarczenie próbki guza przed rozpoczęciem badania

✗ Disqualifies

  • Wcześniejsze leczenie podobnym lekiem (z camptotecyną)
  • Brak apetytu, nudności, wymioty lub objawy niedrożności jelit
  • Poważne choroby płuc
  • Inne poważne zaburzenia zdrowia dyskwalifikujące z badania

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 22, 2026
Sex
No restrictions

Therapies / drugs in trial

Locations (30)

City of Hope National Medical Center

Duarte, United States

City of Hope at Irvine Lennar

Irvine, United States

Ronald Reagan UCLA Medical Center

Los Angeles, United States

UCLA Department of Medicine-Hematology/Oncology

Los Angeles, United States

Santa Monica UCLA Medical Center & Orthopaedic Hospital

Santa Monica, United States

UCLA Hematology/Oncology - Santa Monica

Santa Monica, United States

Smilow Cancer Hospital - Yale New Haven Health

New Haven, United States

Yale - New Haven Hospital - Yale Cancer Center

New Haven, United States

Smilow Cancer Hospital Phase 1 Unit

New Haven, United States

Smilow Cancer Hospital - Trumbull

Trumbull, United States

Brigham and Women's Hospital

Boston, United States

Dana-Farber Cancer Institute

Boston, United States

Dana-Farber Cancer Institute - Chestnut Hill

Newton, United States

Sarah Cannon Research Institute - Pharmacy

Nashville, United States

SCRI Oncology Partners

Nashville, United States

The University of Texas MD Anderson Cancer Center - Conroe

Conroe, United States

University of Texas MD Anderson Cancer Center

Houston, United States

The University of Texas, MD Anderson Cancer Center - West Houston

Houston, United States

The University of Texas, MD Anderson Cancer Center - League City

League City, United States

NEXT Oncology

San Antonio, United States

The University of Texas, MD Anderson Cancer Center - Sugar Land

Sugar Land, United States

Princess Margaret Cancer Centre

Toronto, Canada

Princess Margaret Cancer Centre

Toronto, Canada

McGill University Health Centre

Montreal, Canada

Pan American Center for Oncology Trials, LLC

Rio Piedras, Puerto Rico

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Universitario Fundación Jiménez Díaz

Madrid, Spain

Barts Cancer Centre at St. Bartholomew's Hospital; Queen Mary University of London

London, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/23/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.